Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anti-sense oligo
Biotech
GSK hep B drug cures one-fifth of patients in ‘major step’
After treatment with bepirovirsen, 19% of patients across two phase 3 trials achieved the strictly defined “functional cure” criteria for hep B.
Darren Incorvaia
May 28, 2026 4:30am
The 'diabolical' molecule set to become biotech's next gold rush
Apr 9, 2026 8:00am
FDA illuminates new approval pathway for bespoke gene therapies
Feb 23, 2026 11:30am
GSK's 'functional cure' for hep B proves worth in ph. 3 trials
Jan 7, 2026 6:15am
GSK pays $17.5M for CAMP4 regulatory RNA deal
Dec 18, 2025 7:00am
Lilly pens $13M upfront oligonucleotide AI pact with Creyon Bio
Apr 29, 2025 10:07am
